Recently, a global, open-label, phase III trial has shown that the VEGF-blocking mAb bevacizumab combined with anti–PD-L1 improves overall and progression-free survival outcomes compared with standard-of-care sorafenib in unresectable hepatocellular carcinoma (38, 39). This evidence concerns the gene CD274 and hepatocellular carcinoma.